EGFR and neoplasm: A previous study with linsitinib, crizotinib, and gefitinib that target IGFR1, MET, and EGFR decrease mRNA MYB-NFIB levels or even block protein synthesis, which promote cell differentiation and decrease of tumor growth in vivo and in vitro.